Abstract: The present invention relates to a composition and method for the simultaneous alleviation of the symptoms of inflammation brought about by innate immune responses wherein said composition acts by inhibiting leukotrienes, chemotactic cytokines and cyclooxygenases. The composition of the present invention comprises at least an extract of Butterbur, Bromelain and an extract of White Willow bark.

Abstract: The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

Abstract: Dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours. The supplements and compositions can include a combination of an amino acid, vitamins, herbs and enzymes. The composition/supplement can be put in capsule form and when administered to mammals can reduce these symptoms with approximately two hours. reducing the pain and inflammation associated with chronic joint discomfort, chronic low back pain, muscle strain, arthritis, sports injuries, normal everyday bumps and bruises. The novel composition has also been shown to be very effective in reducing monthly menstrual symptoms (PMS). The novel composition can also have benefits for other ailments such as but not limited to Osteoarthritis, Cardiovascular disease, Neurological ailments, Alzheimer disease, and Cancer.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: A composition and a method for treatment of urinary tract dysfunction and, particularly, non-bacterial cystitis and, even more particularly, non-bacterial chronic interstitial cystitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other cystitis affecting agents, such as cranberry, as well as some other active and non-active ingredients.

Abstract: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.

Abstract: Methods for exterminating pests using compositions comprising at least one protease enzyme. A detergent component may also be utilized in such compositions.

Abstract: Disclosed are alginate formulations that help protect digestive enzymes in the formulations from denaturation during passage through the acidic stomach environment, and from other sources, following ingestion. The formulation changes consistency to permit release of the enzymes in the less-acidic gut. They contain monovalent alginate salts (sodium, potassium and ammonium alginate) but are designed to not include significant quantities of compounds which would generate divalent ions and thereby convert the monovalent alginate to a divalent alginate when exposed to aqueous solution. A buffering agent that does not react with the digestive enzymes or the monovalent alginate, and which does not generate divalent ions on exposure to aqueous solution, can be included. A chelating agent which binds divalent ions may be administered with the formulation. Additionally, the formulation may be admixed with inert excipients suitable for oral delivery. It is preferable that the ingredients are dried before formulation.

Abstract: The present invention provides novel chymopapain isoenzymes, compositions thereof, and methods for locally ad-ministering recombinant chymopapain or synthetic chymopapain to treat a disc disorder. Recombinant chymopapain or synthetic chymopapain useful in the methods of the invention can be naturally occurring chymopapain or variant chymopapain, including the novel chymopapain isoenzmyes of the invention.

Abstract: An improved more comprehensive understanding of tumors is disclosed including a precise molecular etiology leading to tumor cell growth. The disclosed molecular etiology explains the lack of control of tumor cell growth as well as the activation of a variety of phenotypic and pathological molecular mechanisms that are the natural result of the disclosed tumor etiology. A comprehensive approach to the detection and treatment of neoplasia is also disclosed.

Abstract: Methal sulfonyl methane, glucosamine sulfate, folic acid and vitamin B-12 composition for the enhancement of the execution of transmethylation activity within every living cell in the body for humans and all other members of every other genus and species in the entire Animal Kingdom. Elemental Cellular Therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and homeostatic processes.

Abstract: The pain relief composition is a combination of dietary and nutritional supplements that has been found effective for the relief of pain arising from a wide variety of diseases and injuries, regardless of severity or chronicity. The composition is formulated for oral administration, such as a tablet, soft gel capsule, liquid, or the like. The pain relief composition includes: at least one omega fatty acid; at least one antioxidant; and at least one amino acid.

Abstract: A Composition and method for administering a nutritional supplement to an individual, e.g., a human or animal, are provided for the alleviation of joint pain, long-lasting relief from joint pain, improvement of joint functioning as well as help to restore joint flexibility through a reduction of inflammation. The nutritional supplement may include at least Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides and source of Curcuminoids. The nutritional supplement may be provided for consumption at least one time daily.

Abstract: Proteases having mitogenic activity isolated from the genus Carica are provided. In particular the proteases are cysteine proteases isolated from Carica candamarcensis. In addition, the recombinant forms of the protease, including fragments and mutants with substantial homology are provided. Also provided are pharmaceutical compositions useful for treating wounds that include the disclosed proteases with mitogenic activity. A method of treating wounds is provided using the disclosed proteases.

Abstract: treating method for hair growth inhibition, which comprises administering (A) the extract of a plant of the family Juniperus or a malt. In addition, the present invention relates to a dermatologic composition for external use, which comprises (B) an elastase inhibitor or neutral endopeptidase inhibitor, and the above-described component (A) and/or (C) at least one proteolytic enzyme selected from the group consisting of papain, trypsin, chymotrypsin, pepsin, bromelain, ficin and pancreatin.

Abstract: Methods for treating at least one condition of an intervertebral disc (e.g. protrusion, hemiation, discogenic pain, dehydration, or degeneration) in a patient in need thereof are provided. The method comprises placing a device into an intervertebral space of a patient wherein the device comprises: a chemonucleolysis agent in solid form such that, when the device is placed into the nucleus pulposus of the intervertebral disc, it releases the chemonucleoylysis agent into the nuclear disc tissue surrounding the device to proteolytically degrade the tissue; or first or second active agents in solid form wherein the first active agent is different from the second active agent and wherein the device, when placed in the nucleous pulposus of the intervertebral disc, releases the first and second active agents into the nuclear disc tissue surrounding the device.

Abstract: A pharmaceutical composition for relieving the itch, pain, and swelling resulting from insect bites and stings, and methods for producing and using the composition. The method preferably comprises topically applying to the affected area the composition which contains an abrasive ingredient and an anti-itch enzyme, both of which are dispersed in a carrier containing effective amounts of emulsifiers, and/or dispersants and may take the form of a powder, liquid, or paste. The final pharmaceutical composition is preferably made in the form of a cream or lotion so that it can be rubbed directly on the skin at the affected site. The pharmaceutical composition for relieving the itch, pain, and swelling resulting from insect bites and stings disclosed herein may also contain an anesthetic and/or antibiotic.

Abstract: Provided is a kit that composes of two products and its method of use to promote hair growth. The kit has two products that are applied to the scalp of a human sequentially. The first product applied to the scalp of a human is a monoethanolamine salt composition that is combined with an organic enzyme. The second product is an oxidizing agent.

Abstract: The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum. It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene/divinyl-benzene base and/or on base of in particular ceramic hydroxylapatite.

Abstract: Provided are compositions comprising monoethanolamine salts of thioglycolic, salicylic, lactic and glycolic acids in combination with an organic enzyme, preferably papain, and an oxidizing aged their methods of use to induce hair growth in the scalp of humans and other mammals.

Abstract: The present invention relates to a treating method for hair growth inhibition, which comprises administering (A) the extract of a plant of the family Juniperus or a malt. In addition, the present invention relates to a dermatologic composition for external use, which comprises (B) an elastase inhibitor or neutral endopeptidase inhibitor, and the above-described component (A) and/or (C) at least one proteolytic enzyme selected from the group consisting of papain, trypsin, chymotrypsin, pepsin, bromelain, ficin and pancreatin.

Abstract: The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is diminished or destroyed and the patient develops immune memory that inhibits or prevents recurrence of the tumor.

Abstract: The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue.

Abstract: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application to teeth whereby enzyme activity is maintained with improved dentifrice foaming characteristics.

Abstract: The perioperative multivitamin protein additive for promoting an anabolic state in a person, is made of from about 250 mg to about 2500 mg a digestive enzyme, such as bromelain, pepsin, amylase, protease, lipase, cellulase, lactase, alpha-g, glucoamylase, invertase, malt diastase, pectinase, xylanase, bromelain, betain, and trypsin, or combinations thereof; from about 50 mg to about 2500 mg of an amino acid; from about 200 mg to about 2000 mg of a sea plant; from about 10 mg to about 8000 mg of a flavoring; from 100 mg to 2500 mg o Vitamin A, Vitamin B, Vitamin D, Vitamin E, Vitamin K and calcium, complexes thereof, and combinations thereof; and from about 1000 mg to about 9000 mg of a fiber. The perioperative multivitamin protein additive can be added to an ingestible liquid in order to form a perioperative multivitamin protein beverage.

Abstract: The compositions of this invention comprise a mixture of (1) phenylalanine and a dietary food supplement, (2) leucine and a dietary food supplement, and (3) hydrocinnamic acid and a dietary food supplement. The compositions are used for medicinal purposes to alleviate a variety of maladies.

Abstract: The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

Abstract: The present invention is directed to a method of treating a sudden onset of at least one neurological deficit in a subject. The sudden onset of neurological symptoms is an indicator of a possible stroke, also termed a cerebrovascular accident. The method comprises administering an effective amount of melatonin to the subject immediately after the sudden onset of at least one neurological deficit, and preferably within three hours of the sudden onset of the at least one neurological deficit. Preferably, the effective amount of melatonin is at least about 200 mg and less than about 1000 mg, although for a small child or infant the effective amount of melatonin may be less than about 200 mg while for a large adult it may be more than about 1000 mg. It is expected that the effective amount of melatonin is no more than about 1500 mg in almost all cases.

Abstract: Use of an extract of bacterium from the family Pseudomonadaceae in the production of cosmetic compositions in particular for combating ageing of the skin.

Abstract: The present invention relates to the use of bromelaine proteases for inhibiting blood coagulation, especially for stimulating the production of plasmin, for inhibiting the production of fibrin and for inhibiting the adhesion of human thrombocytes on endothelilum cells. Especially the basic proteases isolable from raw bromelaine have proved to be particularly suitable proteases.

Abstract: Novel proteins which belong to the papain family and are cysteine proteinase enzymes (the cysteine proteinase enzymes are expected to be involved in the turnover of intracellular proteins, antigen presentation, prohormone activation, bone remodeling, etc. and to play important roles in a variety of pathological conditions such as Alzheimer's disease, pulmonary emphysema, rheumatoid arthritis, muscular dystrophy, osteoporosis, neurodegenerative disease, and cancer invasion and metastasis), together with genes encoding the proteins and antibodies against the proteins, can be conveniently used in elucidating the function of a cysteine proteinase involved in various diseases and disorders, especially cancers, thereby not only disclosing critical mechanism leading to such diseases and disorders but also researching and developing therapy and therapeutic drugs thereagainst.

Abstract: A composition for use in treating autism spectrum disorders. The composition preferably includes a genomeceutical type compound that increases the user's expression of DPPIV or like substances. The genomeceutical compound may include a sugar (such as a milk sugar), glucans, galactose and/or related material. The composition may also include one or more of a protease, peptidase or phytase. The inclusion of phospholipids, disaccharides, lipases and/or related substances in a composition for treating autism spectrum disorders and the function they provide is also disclosed.

Abstract: The invention provides methods of treating and preventing vascular diseases, by inhibiting cysteine proteases active at sites of vascular injury, particularly cathepsins K and S, by administering cystatin C or TGF-&bgr;1. Cystatin C is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Also provided is a method of diagnosing a patient at risk of, or with, vascular injury by detecting low levels of circulating cystatin C.

Abstract: The present invention provides genes encoding novel matrix metalloproteinases termed MMP; constructs and recombinant host cells incorporating the genes; the MMP polypeptides encoded by the genes; antibodies to the MMP polypeptides; and methods of making and using all of the foregoing.

Abstract: The invention provides compositions such as dietary supplements. Such compositions can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. The invention also provides methods for reducing pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis.

Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.

Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.

Abstract: The present application pertains to the use of bromelain preparing a medicament for increasing the IL-(8) level in an individual so as to reduce or prevent inflammation in said individual and as an adjuvant therapy during wound healing processes.

Abstract: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application to teeth whereby enzyme activity is maintained with improved dentifrice foaming characteristics.

Abstract: A composition and a method for the amelioration of Lupus, related rheumatic and autoimmune diseases such as fibromyalgia and inflammatory joint diseases. The composition consists of a bioflavonoid combined with Bromelain. Vitamin C may be added to the composition to improve its efficacy. The preferred flavonoid is Luteolin or Quercetin. Myricetin may also be used as may be a glycoside such as Rutin that contains either Luteolin, Quercetin or Myricetin as an aglycone. Other effective flavonoids can be selected by their ability to interact with the Kv1.3 channel of lymphocytes. In a preferred method of treatment a mixture of flavonoid, Bromelain and Vitamin C is administered at least daily by an oral route. A mixture of 500 mg Quercetin, 500 mg Bromelain and 500 mg Vitamin C administered three times daily is effective.

Abstract: The invention is directed to dietary supplements including a core of lysine and bromelain and, optionally, including lycopene. Supplements can further include at least one of Vitamin C, Vitamin E, Vitamin B12, CoEnzymeQ10, lycopene, folic acid, selenium, lecithin and quercetin. Supplements can also further include lutein or xanthin. A preferred supplement includes 5000 mg lysine, 125 mg bromelain, 250 mg Vitamin C,800 IU Vitamin E, 500 mcg Vitamin B 12, 200 mg CoEnzymeQ10, 10 mg lycopene, 800 mcg folic acid, 100 mcg selenium, 250 mg quercetin and 2400 mg lecithin. The supplements have dietary uses or can be used to alleviate dementia-related symptoms.

Abstract: The invention involves administration of MMPAP-12 polypeptides and nucleic acids for the treatment or prevention of infectious disease associated with microorganisms in subjects. The invention also relates to kits and compositions relating to the MMPAP-12 molecules.

Abstract: Methods for exterminating pests using compositions comprising at least one protease enzyme. A detergent component may also be utilized in such compositions.

Abstract: A method for the treatment of spinal cord injury is disclosed. The method involves the administration of a therapeutically effective amount of a defibrinogenating or fibrinolytic agent. In accordance with the principles of the invention, also disclosed are a method for the treatment of neuronal and neurological damage associated with or caused by spinal cord injury, a method for minimizing neuronal and neurological damage associated with spinal cord injury, a method for reducing, limiting, and/or delaying scarring at the site of a spinal cord injury, a method for reducing or limiting the development of spontaneously occurring, post-operative or post-traumatic injury spinal adhesions, a method for educing or limiting the development of spontaneously occurring, post-operative or post-traumatic injury spinal tethering and a method for reducing or limiting the pain associated with arachnoiditis. In a preferred aspect of the disclosed methods, the defibrinogenating agent is ancrod.

Abstract: The present invention relates to methods of preventing or decreasing the severity of scarring in a subject comprising: obtaining a pharmaceutical composition comprising a single chain urokinase plasminogen activator molecule (scuPA) or a scuPA mimetic; and administering the pharmaceutical composition to a subject; wherein scarring in the subject is either prevented or decreased relative to an amount of scarring that would be expected if the pharmaceutical composition were not administered to the subject. The invention also relates to methods of screening for compounds that prevent or decrease the severity of scarring in a subject.

Abstract: The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

Abstract: The present invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a purified natural or synthetic epidermis-specific polypeptide which is involved in horny layer cell cohesion. The invention also relates to a cosmetic or pharmaceutical composition comprising a mixture of polypeptides derived from the proteolysis of the purified polypeptide of the present invention. The present invention further relates to a method for strengthening horny layer cell cohesion which comprises applying the cosmetic or pharmaceutical composition of the present invention to the skin. Finally, the present invention relates to a method for reducing horny layer cell cohesion, and thereby promoting exfoliation, wherein said method comprises applying to the skin a cosmetic or pharmaceutical composition comprising an effective amount of at least one protease active on the polypeptide of the present invention.

Abstract: Methods for controlling blood coagulation, and suitable pharmaceutical compositions that include a polypeptide that enhances the anticoagulation process (or inhibitors thereof for reversing the anticoagulation process) are provided.

Abstract: Thiol proteases having Cathepsin 1 type activity are used in the formulation of vaccines for combating helminth parasites. Preferably the protease is derived from a fluke such as Fasciola hepatica.

Abstract: A human tissue inhibitor of metalloproteinases-4 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for the treatment of diseases, including arthritis and cancer. Antagonists against such polypeptides and their use as a therapeutic to resorb scar tissue are also disclosed. Diagnostic assays for detecting levels of human TIMP-4 protein and mutations in human TIMP-4 nucleic acid sequence are also disclosed.